Abstract:The overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway has been examined in various carcinomas and is reported to be significantly correlated with prognosis. However, little is known with regard to the PI3K/Akt signal transduction pathway in advanced non-small cell lung carcinoma (NSCLC). The present study investigated the expression of PI3K and phosphorylated (p)-Akt protein and its clinical significance in NSCLC. The clinical records of 157 patients with NSCLC (70 stage I-IIIA and 87 stage IIIB-IV cases), consisting of 75 cases of squamous cell carcinoma and 82 cases of adenocarcinoma, together with 30 resected lung cancer tumor-adjacent tissue samples, were retrospectively evaluated. PI3K and p-Akt expression in the NSCLC and tumor-adjacent tissues were measured using an immunohistochemical method, and its correlation with the clinicopathological data and prognosis in advanced NSCLC was evaluated. PI3K and p-Akt expression was significantly higher in the cancer tissues (chi(2)=14.8455; P=0.001) than in the tumor-adjacent tissues (chi(2)=14.2615; P=0.001). The overexpression of p-Akt in stage I-IIIA NSCLC was associated with lymph node metastasis (chi(2)=6.1189; P=0.013) and tumor-node-metastasis (TNM) stage (chi(2)=8.9752; P=0.011), however, no correlation was observed with gender, age, pathological type and histological grade. The overexpression of p-Akt in stage IIIB-IV NSCLC was only associated with TNM stage (chi(2)=5.7501; P=0.016), and no correlation was observed with gender, age, Pathological type, histological grade and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The overexpression of PI3K was not found to correlate with the aforementioned clinicopathological variables in all patients. Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 mont hs) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007]. Multivariate analysis showed that PI3K [hazard ratio (HR)=2.143; 95% CI, 1.211-3.790; P=0.009], p-Akt (HR=1.991; 95% CI, 1.009-3.927; P=0.047), TNM stage (HR=4.788; 95% CI, 2.591-8.848; P=0.001) and ECOG-PS (HR=3.272; 95% CI, 1.701-6.296; P=0.001) were independent predictors for survival in stage IIIB-IV NSCLC. These results indicated that p-Akt overexpression closely correlates with factors of an unfavorable prognosis in NSCLC. PI3K and p-Akt overexpression are independent markers of a poor prognosis in advanced NSCLC.

Clinical Significance of Pik3ca and Survivin in Primary Adenosquamous Lung Carcinoma

P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adenocarcinoma

Expression of Survivin and Its Correlation with Expression of Bcl-2 and P53 in Colorectal Adenocarcinoma

Aberrant Expression of SCARA5 in Lung Adenocarcinoma and its Clinical Significance

P2.03b-087 PD-L1 Expression in Adenosquamous Lung Carcinoma and the Comparison with the Other Common Variants of Non-Small Cell Lung Cancer

PI3K expression predicts overall survival in lung adenocarcinoma.

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung

Expression and Clinical Significance of Survivin and Its Correlation with P53 in Lung Squamous Cell Cacinomas and Adenocarcinomas

Clinical Significance Of Visceral Pleural And Lymphovascular Invasion In Surgically Resected Adenosquamous Lung Cancer

[Expression of Survivin and Its Clinical Significance in Non-Small Cell Lung Cancer].

Survival, Radiologic Findings, PD-L1, and Driver Mutations

Expression and Correlations of Survivin、VEGF and P53 in Lung Squamous Cell Cacinomas and Adenocarcinomas

Clinicopathological Characteristics and Survival Outcomes in Adenosquamous Carcinoma of the Lung: a Population-Based Study from the SEER Database.

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.

Clinical Outcomes of Primary Adenosquamous Carcinoma of the Lung Treated by Surgery

Risk Factors of Postoperative Recurrence and Potential Candidate of Adjuvant Radiotherapy in Lung Adenosquamous Carcinoma

Prognostic Significance of P21, P27 and Survivin Protein Expression in Patients with Oral Squamous Cell Carcinoma

[Expression and Clinical Significance of Caspase-3,Survivin and K-Ras in Non-Small Cell Lung Cancer.].

Comprehensive Analysis of Clinicopathological Profiles in Adenosquamous Carcinoma of the Lung.